Chronopin: upcoming release dates, events and other important dates

Development of the Microsoft EAT14 hyperscale data center building at the Malaga Technology Park in Chelan County, Washington. Delivering 57 MW of Azure cloud and AI compute capacity in a 650M USD buildout near Wenatchee, EAT14 utilizes carbon-free Columbia River hydropower delivered by Chelan County PUD.

TotalEnergies Renewables USA is constructing the 150 MWac Laurens Solar Project across rural landholdings near Dublin in Laurens County, Georgia. Interconnecting into the Southern Company and Georgia Power transmission network, the utility-scale solar power complex supports Georgia's clean energy procurement goals while generating substantial long-term tax revenues and construction labor opportunities across central Georgia.

GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.

The United Kingdom and Ireland co-host the European Championship across nine stadiums. Estimated date.

Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

A nuclear-powered rotorcraft that will fly between sites on Saturn's moon Titan, arriving in the 2030s. Scheduled date.

Boralex development of the Fort Covington Clean Solar Energy Center (NY125A) in the Town of Fort Covington, Franklin County, New York. Delivering 250 MWac of utility-scale photovoltaic capacity tied to the New York Power Authority (NYPA) 230 kV Moses–Willis–Plattsburgh transmission corridor, the project expands North Country clean generation.